Abstract Details

Title A Comparison of Coordinated Reset and Low-frequency Vibrotactile Stimulation for the Treatment of Parkinson’s Symptoms

Topic Movement Disorders

Presentation(s) S11 - Movement Disorders: Technological Advances in Diagnostics and Therapeutics (5:06 PM-5:18 PM)

Poster/Presentation
Number 009

Objective The present research examines a novel non-invasive vibrotactile device which stimulates fingertips in a pattern aiming to disrupt pathological physiological beta-band oscillations associated with motor symptoms, particularly bradykinesia, of Parkinson’s Disease (PD). Specifically, we assess whether the therapy reduces symptoms of bradykinesia compared to a sham control of general vibrotactile (VT) stimulation.

Background The paucity of movements in PD may reflect an abnormal stabilization of motor plans, seen in the motor stabilization hypothesis of the beta-band physiological rhythm (15-30 Hz). Recent modeling work shows stimulation provided in a pattern referred to as coordinated reset (CR) can disrupt the pathological oscillations that outlasts the stimulation. Preliminary work shows that CR therapy, delivered as vibrotactile stimulation to the fingertips of both hands, appears to reduce bradykinesia symptoms. The prior findings, however, are limited to small samples and do not include placebo control. Here, we report the results of a study wherein 21 PD participants underwent CR vibrotactile (VT) therapy and sham VT stimulation, with movement assessment after each experimental arm.

Design/Methods Twenty-one PD participants (Hoehn-Yahr 2-4) underwent active CR VT and placebo VT treatment for two months each. Treatment consists of wearing a VT glove that provides stimulation for four hours daily. The study design is a double-blind, random crossover with movement assessed at the end of each arm using an instrumented version of MDS- UPDRS Part III.

Results PD patients exhibit statistically significant reductions in bradykinesia scores after CR VT therapy. However, bradykinesia scores were not significantly affected by general VT therapy.

Conclusions The present findings replicate and build on prior CR VT therapy studies that used small samples and no placebo control. VT therapy represents a promising non-invasive therapy. Importantly, the principle of VT therapy suggests that therapeutic benefits outlast stimulation and may have potential for sustained long-term outcomes.

Authors/Disclosures
Madeline S. Gutierrez PRESENTER	Miss Gutierrez has received personal compensation for serving as an employee of Synergic Medical Technologies Inc..
Elyria Kabasenche	Ms. Kabasenche has received personal compensation for serving as an employee of Synergic Medical Technologies.
Mitchell Fisher, MS	Mr. Fisher has nothing to disclose.
Julia Leach (Cognito Therapeutics, Inc.)	No disclosure on file
Barbara Gaston, PhD	Dr. Gaston has received personal compensation for serving as an employee of Synergic Medical Technologies.
Roma Shusterman, PhD	Dr. Shusterman has nothing to disclose.
Christian Hauptmann, PhD	Dr. Hauptmann has received personal compensation for serving as an employee of curetec GmbH. Dr. Hauptmann has stock in curetec GmbH. Dr. Hauptmann has received intellectual property interests from a discovery or technology relating to health care.
Don M. Tucker, PhD (Electrical Geodesics, Inc.)	Dr. Tucker has received personal compensation for serving as an employee of Brain Electrophysiology Company.
Phan Luu, PhD	Mr. Luu has received personal compensation for serving as an employee of Synergic Med. Tech.

��ɫ��

��ɫ��